NuVasive Announces Change of Venue for Investor Event -- Now at

NuVasive Announces Change of Venue for Investor Event -- Now at the W
Hotel at Union Square Park 
SAN DIEGO, CA -- (Marketwire) -- 11/11/12 --  NuVasive, Inc. (NASDAQ:
NUVA), a medical device company focused on developing minimally
disruptive surgical products and procedures for the spine, announced
today that due to continued transportation difficulty around New York
City, the venue for the Company's Investor Event has been moved to
the W Hotel at 201 Park Avenue South in New York, New York.  
The event is still planned to take place on Wednesday, November 14,
2012 from 9:00 a.m. - 12:00 p.m. ET. Registration, breakfast, and
product demonstrations will still commence at 8:45 a.m., followed by
the formal presentation from 9:30 a.m. to 12:00 p.m. 
The event will be hosted by Alex Lukianov, Chairman and Chief
Executive Officer, and will feature a panel of leading U.S. spine
surgeons. As well, Keith Valentine, President and Chief Operating
Officer will provide a product overview, Michael Lambert, Executive
Vice President and Chief Financial Officer, will provide a financial
update, and Kelli Howell, Vice President of Research, will present a
strategic update on NuVasive's clinical efforts.  
The agenda will include: 


 
--  Executive management's plan to re-establish momentum and address
    industry challenges
    
    
--  A review of the company's key growth drivers, future catalysts, and
    financial projections
    
    
--  A sawbones demonstration of the Company's recently approved PCM(R)
    Cervical Disc including clinical support references and direct
    comparisons to competitive devices
    
    
--  Clinical evidence demonstrating the advantages of XLIF compared to
    other approaches for spine fusion and to other lateral products
    
    
--  A discussion about the state of the U.S. Spine Market and an overview
    of the competitive dynamics by NuVasive sales executives
    
    
--  An in depth review of the breadth and depth of the Company's product
    portfolio, including recent product launches at NASS and the game
    changing product roadmap for the future
    
    
--  An update on the Company's expansion outside the United States
    
    
--  Ample time for audience Q&A

  
Alive webcast
 of the meeting will be available online from the
investor relations page of the Company's corporate website at
www.nuvasive.com. After the live webcast, the presentation will
remain available on the website for 30 days.  
About NuVasive 
NuVasive is a medical device company focused on developing minimally
disruptive surgical products and procedurally integrated solutions
for the spine. The Company is the 4th largest player in the $7.9
billion global spine market. 
NuVasive's principal product offering is based on its Maximum Access
Surgery, or MAS(R) platform. The MAS platform combines several
categories of solutions that collectively minimize soft tissue
disruption during spine surgery with maximum visualization and safe,
easy reproducibility for the surgeon: a proprietary software-driven
nerve avoidance system and intra-operative monitoring support;
MaXcess(R), a unique split-blade retractor system; a wide variety of
specialized implants; and several biologic fusion enhancers. MAS
significantly reduces surgery time and returns patients to activities
of daily living much faster than conventional approaches. Having
redefined spine surgery with the MAS platform's lateral approach,
known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has
built an entire spine franchise. With over 75 products today spanning
lumbar, thoracic and cervical applications, the Company will continue
to expand and evolve its offering predicated on its R&D focus and
dedication to outstanding service levels supported by a culture of
Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to: the
uncertain process of seeking regulatory approval or clearance for
NuVasive's products or devices, including risks that such process
could be significantly delayed; the possibility that the FDA may
require significant changes to NuVasive's products or clinical
studies; the risk that products may not perform as intended and may
therefore not achieve commercial success; the risk that competitors
may develop superior products or may have a greater market position
enabling more successful commercialization; the risk that insurance
payers may refuse to reimburse healthcare providers for the use of
NuVasive's products the risk that additional clinical data may call
into question the benefits of NuVasive's products to patients,
hospitals and surgeons; and other risks and uncertainties more fully
described in NuVasive's press releases and periodic filings with the
Securities and Exchange Commission. NuVasive's public filings with
the Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking
statement to reflect events or circumstances arising after the date
on which it was made. 
Contact: 
Michael J. Lambert 
EVP & Chief Financial Officer 
NuVasive, Inc. 
858.909.3394 
investorrelations@nuvasive.com  
Investors:
Patrick F. Williams 
Vice President, Strategy & Investor Relations
NuVasive, Inc.
858-638-5511
investorrelations@nuvasive.com  
Media: 
Nicholas S. Laudico
The Ruth Group
646-536-7030
nlaudico@theruthgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.